Search Result

Results for "

FFAs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adrenergic Receptor (1) Autophagy (5) COX (2) Free Fatty Acid Receptor (25) Isotope-Labeled Compounds (1) MMP (2) nAChR (1) P2X Receptor (1) Potassium Channel (1) PPAR (2) Reactive Oxygen Species (3)
By Research Areas:	Cardiovascular Disease (8) Inflammation/Immunology (5) Metabolic Disease (34) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111143

SCH-900271	nAChR	Metabolic Disease
SCH-900271 is an orally active, potent nicotinic acid receptor (NAR) agonist with an EC₅₀ of 2 nM in the hu-GPR109a assay. SCH-900271 exhibits dose-dependent inhibition of plasma free fatty acid (FFA). SCH-900271 has an improved therapeutic window to flushing .

HY-136896

FFA3 agonist 1	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
FFA3 agonist 1 is an agonist of free fatty acid receptor 3 (FFA3). FFA3 agonist 1 regulates the health effect of intestinal microbiota by activating FFA3 .

HY-15697

TUG-770 3 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-770 is a potent, selective and orally active *GPR40/FFA1* agonist with an EC₅₀ of 6 nM for human FFA1. TUG-770 shows a high selectivity for *FFA1* over FFA2, FFA3, FFA4, PPARγ, other receptors, transporters, and enzymes. TUG-770 can be uesd for type 2 diabetes research . TUG-770 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-112813

TUG-1375 3 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-19996

AH-7614 2 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
AH-7614 is a potent and selective FFA4 (GPR120) antagonist, with pIC₅₀s of 7.1, 8.1, and 8.1 for human, mouse, and rat FFA4, respectively. AH-7614 has selectivity for FFA4 over FFA1 (pIC₅₀<4.6). AH-7614 is able to block effects of both the polyunsaturated ω-6 fatty acid linoleic acid and the synthetic FFA4 agonist .

HY-12940

GLPG0974 Maximum Cited Publications 9 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC₅₀ of 9 nM.

HY-116263

CATPB 1 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
CATPB is a potent, selective free fatty acid receptor 2 (FFA2R/GPR43) antagonist .

HY-123297

TUG-469	Free Fatty Acid Receptor	Metabolic Disease
TUG-469 is a selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ value of 19 nM. TUG-469 is >200-fold selective for FFA1 over FFA4. TUG-469 significantly improves glucose tolerance in pre-diabetic mice. TUG-469 can be used for the research of diabetes .

HY-135763

Metabolex-36 Met-36	Others	Others
Metabolex-36 is a FFA4 agonist developed by Metabolex (now Cymabay Therapeutics) and used in multiple studies to investigate the function of FFA4. Metabolex-36 was used in conjunction with AstraZeneca compounds (AZ-423 and AZ-670) to investigate FFA4 function in pancreatic delta cells. Metabolex-36 has a pEC50 of 5.9 for FFA4 and a pEC50 of less than 4.0 for FFA1. Compound B was used to investigate the role of FFA4 in growth hormone-releasing peptide (ghrelin) secretion and somatostatin release and was used with FFA4 KO mice. Compound B had an EC50 of 15 nM for FFA4 in an IP3 accumulation assay in FFA4-transfected COS7 cells and was up to 1000-fold selective for FFA1. Compound B inhibited baseline ghrelin secretion from primary gastric mucosal cells but had no effect on cells from FFA4 KO mice. Oral administration of Compound B reduced plasma ghrelin levels in mice under starvation conditions. Compound B also inhibited somatostatin release from primary gastric epithelial cells but had no effect on cells from FFA4 KO mice.

HY-147987

FFA1 agonist-1	Free Fatty Acid Receptor	Metabolic Disease
FFA1 agonist-1 (Compound 17a) is an orally active fatty acid receptor 1 (FFA1) agonist with an EC₅₀ of 0.75 μM. FFA1 agonist-1 can be used for type 2 diabetes mellitus research .

HY-13467

AM-1638 2 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
AM-1638 is a potent and orally bioavailable *GPR40/FFA1* full agonist with an EC₅₀ of 0.16 μM.

HY-19995

GSK137647A 1 Publications Verification GSK 137647	Free Fatty Acid Receptor	Metabolic Disease
GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC₅₀ values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC₅₀ values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response .

HY-100881

TUG-891 5+ Cited Publications	Free Fatty Acid Receptor	Metabolic Disease
TUG-891 is a potent and selective agonist for the long chain free fatty acid (LCFA) receptor 4 (FFA4/GPR120) .

HY-139175

ZLY032	Others	Others
ZLY032 is a dual FFA1/PPARδ agonist with the activity of improving glucose and lipid metabolism, alleviating liver fibrosis, and potentially inhibiting metabolic disorders.

HY-P1125

4-CMTB 2 Publications Verification	Free Fatty Acid Receptor	Others
4-CMTB is a selective free fatty acid receptor 2 (FFA2/GPR43) agonist and a positive allosteric modulator (pEC₅₀=6.38) .

HY-129136

TUG-1387	Others	Others
TUG-1387 is a analog of both AH-7614 and TUG-1506 that has no activity at FFA4. TUG-1387 can serve as negative control for studies assessing FFA4 function.

HY-129707

AMG 837 hemicalcium	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 hemicalcium is a potent, orally bioavailable and partial agonist of *GPR40/FFA1. AMG 837 hemicalcium inhibits specific [ ³H]AMG 837 binding at the human FFA1 receptor with a pIC₅₀* of 8.13. AMG 837 hemicalcium could enhance insulin secretion and lower glucose levels in rodents .

HY-12940A

(S)-GLPG0974	Free Fatty Acid Receptor	Metabolic Disease
(S)-GLPG0974 is the isomer of GLPG0974 (HY-12940), and can be used as an experimental control. GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC₅₀ of 9 nM.

HY-14363

TUG-424	Free Fatty Acid Receptor	Metabolic Disease
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity . TUG-424 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19842

GS-9667 CVT 3619	Adenosine Receptor	Cardiovascular Disease Metabolic Disease
GS-9667 (CVT 3619), a novel N ⁶-5'-substituted adenosine analog, is a selective, partial agonist of the A₁ adenosine receptor (A₁AdoR). GS-9667 binds to adipocyte membranes with high (K_H=14 nM) and low (K_L=5.4 μM) affinities. GS-9667 reduces cyclic AMP content and release of nonesterified fatty acids from epididymal adipocytes with IC₅₀ values of 6 nM and 44 nM, respectively. GS-9667 inhibits lipolysis and has the potential for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA) .

HY-13967B

AMG 837 calcium hydrate 1 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
AMG 837 calcium hydrate is a potent, orally bioavailable and partial agonist of *GPR40/FFA1. AMG 837 calcium hydrate inhibits specific [ ³H]AMG 837 binding at the human FFA1 receptor with a pIC₅₀* of 8.13. AMG 837 calcium hydrate could enhance insulin secretion and lower glucose levels in rodents . AMG 837 (calcium hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130120

HWL-088	Free Fatty Acid Receptor PPAR	Metabolic Disease
HWL-088 is a highly potent and orally active free fatty acid receptor 1 (FFA1/GPR40) agonist (EC₅₀ of 18.9 nM) with moderate PPARδ activity (EC₅₀ of 570.9 nM) . HWL-088 improves glucose and lipid metabolism, and has anti-diabetic effects .

HY-50162

GPR120 modulator 1	Free Fatty Acid Receptor	Metabolic Disease
GPR120 modulator 1 is a G protein coupled receptor 120 (GPR120) modulator extracted from patent US8394841B2, compound example F1. GPR120 modulator 1 can be used for the research of diseases associated with abnormal or deregulated GPR120, such as diabetes .

HY-50172

GPR120 modulator 2	Free Fatty Acid Receptor	Metabolic Disease
GPR120 modulator 2 is a G protein coupled receptor 120 (GPR120) modulator extracted from patent US8394841B2, compound example F13. GPR120 modulator 2 can be used for the research of diseases associated with abnormal or deregulated GPR120, such as diabetes .

HY-N7907

Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside	Others	Metabolic Disease
Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside is a natural product that can be obtained from sphaerophysa salsula. Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside inhibits triglyceride (TG) accumulation in 3T3-L1 adipocytes .

HY-103083

GPR40 agonist 4	Free Fatty Acid Receptor	Metabolic Disease
GPR40 agonist 4 is a potent free fatty acid receptor 1 (FFA1/ GPR40) agonist with a pEC₅₀ of 7.54.

HY-160602

CPL207280	Free Fatty Acid Receptor	Metabolic Disease
CPL207280 is an orally active *GPR40/FFA1* agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .

HY-114011

AMG7703	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
AMG7703 is a selective and allosteric agonists of *FFA2* (GPR43), the receptor for short-chain fatty acids (SCFAs), acetate, and propionate. AMG7703 can be used to research for in inflammatory and metabolic .

HY-121140

AZ1729	Free Fatty Acid Receptor	Metabolic Disease
AZ1729 is a potent free fatty acid 2 receptor (FFA2) activator, acting as a direct allosteric agonist and as a positive allosteric modulator. AZ1729 increases the activity of the endogenously produced short chain fatty acid propionate in G_i-mediated pathways, but not at those transduced by G_q/G₁₁. AZ1729 induces inhibition of isoproterenol-induced lipolysis in mouse adipocytes. AZ1729 also can Induce migration of human neutrophils. AZ1729 can be used for researching the signaling pathways of the physiological roles of FFA2 .

HY-122120

Rafabegron AJ‐9677	Adrenergic Receptor	Metabolic Disease
Rafabegron (AJ-9677) is a specific beta3-adrenoceptor agonist. Rafabegron can reduce blood glucose, insulin, FFA, and triglyceride levels in diabetic and obese mouse models .

HY-B0283

Acipimox 1 Publications Verification K-9321	Others	Metabolic Disease
Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .

HY-B0283A

Acipimox sodium K-9321 sodium	Others	Metabolic Disease
Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .

HY-B0283S

Acipimox-d4 K-9321-d₄	Isotope-Labeled Compounds	Metabolic Disease
Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .

HY-148418

TUG-499	Free Fatty Acid Receptor	Metabolic Disease
TUG-499 is a selective free fatty acid receptor 1 (FFAR1 or GPR40) (Free Fatty Acid Receptor) agonist with a pEC₅₀ of 7.39. TUG-499 exhibits >100-fold selectivity over the related receptors FFA2, FFA3, and the nuclear receptor PPARγ and other diverse receptors, ion channels, and transporters. TUG-499 can be used for the research of type 2 diabetes . TUG-499 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B0283R

Acipimox (Standard)	Others	Metabolic Disease
Acipimox (Standard) is the analytical standard of Acipimox. This product is intended for research and analytical applications. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .

HY-N1478

Gardenoside	P2X Receptor	Neurological Disease
Gardenoside is a natural compound found in Gardenia fruits, with hepatoprotective properties. Gardenoside suppresses the pain of chronic constriction injury by regulating the P2X3 and P2X7 receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis .

HY-N8466

(-)-Lyoniresinol 9'-O-glucoside	Reactive Oxygen Species	Metabolic Disease
(-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .

HY-B0968

Trimetazidine dihydrochloride 5 Publications Verification	Autophagy	Cardiovascular Disease
Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor .

HY-B0968A

Trimetazidine 5 Publications Verification	Autophagy	Cardiovascular Disease
Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor .

HY-N8144

Niga-ichigoside F1	Others	Cardiovascular Disease
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .

HY-B0968S

Trimetazidine-d8 dihydrochloride	Autophagy	Cardiovascular Disease
Trimetazidine-d₈ (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].

HY-B0968AR

Trimetazidine (Standard)	Autophagy	Cardiovascular Disease
Trimetazidine (Standard) is the analytical standard of Trimetazidine. This product is intended for research and analytical applications. Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor .

HY-B0968R

Trimetazidine dihydrochloride (Standard) 5 Publications Verification	Autophagy	Cardiovascular Disease
Trimetazidine (dihydrochloride) (Standard) is the analytical standard of Trimetazidine (dihydrochloride). This product is intended for research and analytical applications. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC₅₀ of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor .

HY-121542

PPARδ agonist 10	PPAR	Metabolic Disease
PPARδ agonist 10 (compound 7) is an orally active, selective, and partial agonist of PPARδ, with EC₅₀ values of 0.053 μM and 0.30 µM for hPPARδ(LBD)-GAL4 and mPPARδ, respectively. PPARδ agonist 10 is a partial PPARδ agonist in transactivation assay but a full agonist on free fatty acids (FFA) oxidation in muscle cells both in vitro and in vivo. PPARδ agonist 10 can be used for dyslipidemia research .

HY-15589

GW9508 5 Publications Verification	Free Fatty Acid Receptor Potassium Channel	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GW9508 is a potent and selective *G protein-coupled receptors FFA1 (GPR40)* and GPR120 agonist with pEC₅₀s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (K_ATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .

HY-114911

Feprazone DA2370; Prenazone; Zepelin	COX Reactive Oxygen Species MMP	Inflammation/Immunology
Feprazone (DA2370; Prenazone), an analogue of Phenylbutazone (HY-B0230), is a nonsteroidal anti-inflammatory agent with analgesic and antipyretic activities. Feprazone acts by inhibiting the activity of cyclooxygenase (COX)-2. Feprazone ameliorates free fatty acid (FFA)-induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS). Feprazone can decrease the expression of MMP-2 and MMP-9. Besides, Feprazone can suppress adipogenesis and increase lipolysis in differentiating 3 T3-L1 cells. Feprazone also can be used to research atherosclerosis and obesity .

HY-114911R

Feprazone (Standard)	COX Reactive Oxygen Species MMP	Inflammation/Immunology
Feprazone (Standard) is the analytical standard of Feprazone. This product is intended for research and analytical applications. Feprazone (DA2370; Prenazone), an analogue of Phenylbutazone (HY-B0230), is a nonsteroidal anti-inflammatory agent with analgesic and antipyretic activities. Feprazone acts by inhibiting the activity of cyclooxygenase (COX)-2. Feprazone ameliorates free fatty acid (FFA)-induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS). Feprazone can decrease the expression of MMP-2 and MMP-9. Besides, Feprazone can suppress adipogenesis and increase lipolysis in differentiating 3 T3-L1 cells. Feprazone also can be used to research atherosclerosis and obesity .

Cat. No.	Product Name

HY-L182

Fatty Acids Compound Library

296 compounds

Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases.

MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1478

Gardenoside	Structural Classification Iridoids Terpenoids Source classification Rubiaceae Plants Gardenia jasminoides Ellis	P2X Receptor
Gardenoside is a natural compound found in Gardenia fruits, with hepatoprotective properties. Gardenoside suppresses the pain of chronic constriction injury by regulating the P2X3 and P2X7 receptors. Gardenoside has an inhibitory effect on free fatty acids (FFA)-induced cellular steatosis .

HY-N8144

Niga-ichigoside F1	Cardiovascular Disease Rhynchosia volubilis Lour. Triterpenes Classification of Application Fields Terpenoids Labiatae Source classification Plants Disease Research Fields	Others
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .

HY-N7907

Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside	Structural Classification Leguminosae Phenols Polyphenols Plants Sphaerophysa salsula	Others
Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside is a natural product that can be obtained from sphaerophysa salsula. Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside inhibits triglyceride (TG) accumulation in 3T3-L1 adipocytes .

HY-N8466

(-)-Lyoniresinol 9'-O-glucoside	Structural Classification Albizia julibrissin Durazz. Leguminosae Source classification Plants Saccharides Monosaccharides	Reactive Oxygen Species
(-)-Lyoniresinol 9'-O-glucoside is an inhibitor of ROS. (-)-Lyoniresinol 9'-O-glucoside reduces lipid accumulation and lipid metabolic disorders in FFAs-exposed HepG2 cells. (-)-Lyoniresinol 9'-O-glucoside inhibits high glucose-induced reactive oxygen species production .

Cat. No.	Product Name	Chemical Structure

HY-B0968S

Trimetazidine-d8 dihydrochloride

Trimetazidine-d₈ (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].

HY-B0283S

Acipimox-d4
Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

FFAs

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Isotope-Labeled Compounds

Natural
Products